Dr David West, Clarity’s founder and Chief Scientific Officer. A graduate from the University of Birmingham with a PhD in microbial genetics, Dr West went on to lead a project at CAMR (now part of the Health Protection Agency at Porton Down) for the development of vaccines for meningococcal meningitis. Dr. West left CAMR in 2000 to join a senior colleague in setting up Regma BioTechnologies, a phage therapy company whose principal therapeutic target was tuberculosis. With this combination of experience, Dr. West has been involved in almost every aspect of the drug development process from the bench stage to developing patent strategies, optimising products for GMP scale-up and negotiating regulatory requirements.
Hugh Ballantine Dykes, Clarity’s Chief Executive Officer. A graduate from Durham University and with an MBA from the Open University, Mr Ballantine Dykes spent eleven years with Vickers Plc, Medical Division, developing international markets for medical intensive care devices. Following a period of six years running an international healthcare marketing consultancy, he joined Dstl (formerly DERA) in 1999 to identify technologies developed for military use, raise investment funding and exploit them for civilian diagnostic and biotech applications.
He was instrumental in launching several spin-out companies including Acolyte Biomedica (MRSA detection) and Alaska Food Diagnostics (food pathogen detection), until in 2003 he joined Alaska as full time Operations Director. He brings a combination of business development, technology exploitation and general management experience to lead Clarity in its next stage of growth.
Dr Edward Regan, Senior Scientist at Clarity. A graduate from the University of York (BSc Biochemistry) and the University of Bristol (MSc Neuroscience, PhD), Dr Regan received his PhD in 2009. He has worked on multiple research projects involving electronics manufacturers (Aptina Imaging, Micron, Toshiba) to develop biosensor platforms for commercialisation and clinical use.
These research projects have involved developing platforms for automated cancer detection by integrating electrochemical sensors and digital microfluidics (University of Toronto), toxin detection using electrical impedance spectroscopy biosensors with DNA aptamers (University of Bath) and neural-interfacing using CMOS-based neuro-chips (University of Bristol). He has also held a position as analytical radiochemist at British Nuclear Fuels Ltd (BNFL/Magnox).
Dr Regan is currently part of the team involved in designing, developing and testing the assay system and instrumentation at Clarity.
Dr. David Rooke, Consultant to Clarity, has worked in the pharmaceutical industry for over 35 years. Formerly head of pharmaceutical development at SmithKline Beecham, he was responsible for developing many products from discovery to commercial benefit in a variety of therapeutic areas and treatment types. He has been a consultant to the industry for more than 15 years and is the founder and director of three pharmaceutical consultancy and knowledge management companies: ProTEM Services and Good Training Practice (GTP) in the UK and Technicas de Deseno y Validacion (TDV) based in Barcelona. TDV is recognised as one of the foremost pharmaceutical consultancies in Spain. Dr. Rooke is an advisory board member at Brunel University Institute of Bioengineering and was instrumental in the first major technology spin out, Dynamic Extractions, where he is still a key investor and director. He is currently involved in evaluating other potential technology applications both at Brunel and other university and technology centres in the UK.